METTL14 and early-onset autosomal dominant Alzheimer disease: Tissue-specific delivery systems based on lipid nanoparticles or viral vectors (such as METTL14 activators targeting blood-brain barrier penetration for the treatment of Alzheimer’s disease) will become a research hotspot.